- Home
- MFIN vs GLSI Comparison
MFIN vs GLSI Comparison
Compare MFIN & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFIN
- GLSI
- Stock Information
- Founded
- MFIN 1995
- GLSI 2006
- Country
- MFIN United States
- GLSI United States
- Employees
- MFIN N/A
- GLSI N/A
- Industry
- MFIN Finance: Consumer Services
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- MFIN Finance
- GLSI Health Care
- Exchange
- MFIN Nasdaq
- GLSI Nasdaq
- Market Cap
- MFIN 224.2M
- GLSI 133.4M
- IPO Year
- MFIN 1996
- GLSI 2020
- Fundamental
- Price
- MFIN $9.79
- GLSI $10.03
- Analyst Decision
- MFIN
- GLSI Strong Buy
- Analyst Count
- MFIN 0
- GLSI 1
- Target Price
- MFIN N/A
- GLSI $39.00
- AVG Volume (30 Days)
- MFIN 71.2K
- GLSI 39.7K
- Earning Date
- MFIN 07-29-2025
- GLSI 08-13-2025
- Dividend Yield
- MFIN 4.90%
- GLSI N/A
- EPS Growth
- MFIN N/A
- GLSI N/A
- EPS
- MFIN 1.60
- GLSI N/A
- Revenue
- MFIN $316,751,000.00
- GLSI N/A
- Revenue This Year
- MFIN N/A
- GLSI N/A
- Revenue Next Year
- MFIN $5.24
- GLSI N/A
- P/E Ratio
- MFIN $6.11
- GLSI N/A
- Revenue Growth
- MFIN 13.91
- GLSI N/A
- 52 Week Low
- MFIN $7.21
- GLSI $8.06
- 52 Week High
- MFIN $10.50
- GLSI $17.49
- Technical
- Relative Strength Index (RSI)
- MFIN 58.96
- GLSI 63.80
- Support Level
- MFIN $9.31
- GLSI $8.97
- Resistance Level
- MFIN $10.19
- GLSI $9.19
- Average True Range (ATR)
- MFIN 0.41
- GLSI 0.37
- MACD
- MFIN 0.05
- GLSI 0.11
- Stochastic Oscillator
- MFIN 73.29
- GLSI 87.11
About MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The five operating segments are, (1) recreation, (2) home improvement, (3) commercial, (4) taxi medallion, and (5) strategic partnership loans. The company generates maximum revenue from the Recreation segment.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.